Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
What does it do?
Roche is a Swiss giant that makes two things: medicines and medical tests. On the medicine side, they make some of the world's best-known cancer drugs — like Herceptin and Avastin — that doctors use to treat breast cancer, lung cancer, and more. On the testing side, they make the machines and kits hospitals use to diagnose diseases, from cancer to HIV to COVID-19. Think of them as both the company that makes the cure and the company that figures out what's wrong with you in the first place.
Roche is one of the largest healthcare companies on the planet, with a market cap of $329 billion, making it a bellwether for the entire pharmaceutical industry. Investors are watching closely right now because several of Roche's biggest blockbuster drugs have lost patent protection, meaning cheaper copycat versions are eating into sales — and the company's future depends on whether its newer drugs can fill that gap. On top of that, Roche is making a major push into personalised medicine and neuroscience, two areas that could reshape healthcare over the next decade.
How does it make money?
Roche makes money through two business segments. The Pharmaceuticals division — which generates the bulk of revenue — sells prescription drugs, predominantly cancer treatments, to hospitals and healthcare systems worldwide. The Diagnostics division sells testing equipment and consumables (the chemical kits that machines need to run tests) to labs and hospitals. Total revenue came in at $61.5 billion last year, up from $60.5 billion the prior year, with net income of $12.9 billion — meaning roughly 21 cents of profit for every dollar of sales, which is a healthy margin for a company this size.
Why do investors care?
The core investment story is about whether Roche can successfully transition away from ageing blockbuster drugs toward a new generation of treatments. Its legacy cancer drugs — Avastin, Herceptin, and Rituxan — are all now facing biosimilar competition (cheaper, near-identical versions made by rivals), which has been a real headwind. The bull case rests on newer drugs like Ocrevus for multiple sclerosis, Hemlibra for haemophilia, and a promising pipeline in Alzheimer's and obesity — areas where a single successful drug can generate billions. For this story to work, Roche needs its pipeline to deliver, and it needs its diagnostics arm to keep growing as global demand for precision testing rises.
Deep Dive
MemberA full investor briefing on Roche Holding AG — history, leadership, risks, and outlook.